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Abstract
Objectives: The Addenbrooke’s Cognitive Examination (ACE) is a common cognitive screening test for dementia. Here,
we examined the relationship between the most recent version (ACE-III) and its predecessor (ACE-R), determined ACE-
III cutoff scores for the detection of dementia, and explored its relationship with functional ability. Methods: Study 1
included 199 dementia patients and 52 healthy controls who completed the ACE-III and ACE-R. ACE-III total and
domain scores were regressed on their corresponding ACE-R values to obtain conversion formulae. Study 2 included 331
mixed dementia patients and 87 controls to establish the optimal ACE-III cutoff scores for the detection of dementia using
receiver operator curve analysis. Study 3 included 194 dementia patients and their carers to investigate the relationship
between ACE-III total score and functional ability. Results: Study 1: ACE-III and ACE-R scores differed by ≤1 point
overall, the magnitude varying according to dementia type. Study 2: a new lower bound cutoff ACE-III score of 84/100 to
detect dementia was identified (compared with 82 for the ACE-R). The upper bound cutoff score of 88/100 was retained.
Study 3: ACE-III scores were significantly related to functional ability on the Clinical Dementia Rating Scale across all
dementia syndromes, except for semantic dementia. Conclusions: This study represents one of the largest and most clini-
cally diverse investigations of the ACE-III. Our results demonstrate that the ACE-III is an acceptable alternative to the
ACE-R. In addition, ACE-III performance has broader clinical implications in that it relates to carer reports of functional
impairment in most common dementias. (JINS, 2018, 24, 854–863)
Keywords: Alzheimer’s disease, Frontotemporal dementia, cognitive screening test, Neuropsychological assessment,
Clinical Dementia Rating scale, Activities of daily living
INTRODUCTION
Brief and accurate cognitive screening tools that can reliably
identify and map cognitive changes over time are essential for
use in cognitive disorders and dementia clinics. Early identi-
fication of such cognitive changes enables timely psychosocial
interventions and support services that can maximize quality
of life for both the person with dementia and their carers (de
Vugt & Verhey, 2013; DeKosky & Marek, 2003).
One screening tool is the Addenbrooke’s Cognitive Exam-
ination (ACE) (Mathuranath, Nestor, Berrios, Rakowicz, &
Hodges, 2000). The ACE was developed to address the poor
coverage of cognitive domains and low diagnostic accuracy of
another popular screening tool, the Mini-Mental State Exam-
ination (MMSE) (Folstein, Folstein, & McHugh, 1975). The
ACE examines the integrity of five cognitive domains (atten-
tion and orientation, memory, verbal fluency, language, and
visuospatial skills), summed to create a total score out of 100
points. The ACE also contains the MMSE items, so that this
score could be generated from the ACE results.
In its second iteration, the ACE-R expanded the scope of
some subtests, and introduced five defined cognitive domain
subscores (Mioshi, Dawson, Mitchell, Arnold, & Hodges,
2006). The most recent revision, the ACE-III, was initiated in
part to address the copyright issue associated with the MMSE
items. As such, the MMSE items, which were part of the
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ACE-R, were replaced with items with similar face validity
and difficulty (Hsieh, Schubert, Hoon, Mioshi, & Hodges,
2013). Additional improvements included the removal of
items that were too culturally specific (“No ifs, ands, or buts”)
(Valcour, Masaki, & Blanchette, 2002), had low correlations
with each other despite putatively loading on the same
domain (Serial 7 Subtraction and Spelling WORLD back-
ward) (Ganguli et al., 1990), or suffered from ceiling effects
(the comprehension items) (Brugnolo et al., 2009).
Validation studies have shown the domain scores of the
ACE-III to have good convergent validity with other stan-
dardized neuropsychological tests. There were significant
correlations between the language domain score and the
Sydney Language Battery total score (r= 0.86), the visuos-
patial domain and the Rey-Osterrieth Complex Figure Copy
score (r= 0.77), the attention domain and Digit Span total
score (r= 0.42), and the memory domain and performance on
the immediate recall trial of the Rey Auditory Verbal
Learning Test (r= 0.59) (Hsieh et al., 2013; Matias-Guiu,
Cortes-Martinez, et al., 2017).
The ACE-III is also sensitive to cognitive changes on a
spectrum from mild cognitive impairment to severe dementia
(Jubb & Evans, 2015; Matias-Guiu, Cortes-Martinez, et al.,
2017). The ACE-III is used worldwide and is available in
several languages (Matías-Guiu et al., 2016; Pigliautile et al.,
2011; Torralva et al., 2011; Yoshida et al., 2012), many of
which are freely available from our website (www.ftdrg.org).
Importantly, the diagnostic accuracy of the ACE-III is as
good, if not better, than other standardized screening instru-
ments, including the Rowland Universal Dementia Assess-
ment Scale (RUDAS), the Montreal Cognitive Assessment
(MoCA), the Memory Impairment Screen (MIS), and the
MMSE (Cheung et al., 2015; Matias-Guiu, Valles-Salgado,
et al., 2017). Importantly, our own studies have shown that
the sensitivity and specificity of the ACE-III are similar to
those of the ACE-R at the cutoffs previously recommended:
88 (sensitivity= 1.0; specificity= 0.96) and 82 (sensitiv-
ity= 0.93; specificity= 1.0) (Hsieh et al., 2013).
Several questions, however, remain. First, it is unclear
whether scores on the ACE-R and ACE-III are directly
comparable. Indeed, direct comparisons between the two
versions of the test, or whether the scores need to be con-
verted (and by how much), have not yet been reported. Sec-
ond, in keeping with previous versions, the ACE-III proposes
two cutoff scores to detect dementia: 88 and 82/100.
Although these ACE-III scores appear to retain similar sen-
sitivity and specificity to the ACE-R, they may vary
depending on dementia subtype and/or context (Elamin,
Holloway, Bak, & Pal, 2016; Hsieh et al., 2013; Jubb &
Evans, 2015). Moreover, these scores were derived in rela-
tively small populations of less than 100 patients, and the
only studies with larger sample sizes have been conducted in
non-English speaking countries (Matias-Guiu, Cortes-
Martinez et al., 2017; Qassem et al., 2015). Large studies
are, therefore, needed to confirm the cutoff scores and to
characterize normal performance on the ACE-III in healthy
English-speaking older adults.
Finally, to date, the relationship between ACE-III perfor-
mance and everyday functioning has not been systematically
examined. How overall cognition is related to an individual’s
functional capacity and whether this relationship is similar
across different clinical syndromes has been relatively
underexplored. This is an important variable to consider,
given the diversity of clinical dementia presentations, and
their likely variability across daily functioning and cognitive
deficits (Hodges, Bozeat, Ralph, Patterson, & Spatt, 2000;
Mioshi et al., 2007). For instance, patients presenting with
predominant memory (Alzheimer’s disease: AD), behavior
(behavioral-variant frontotemporal dementia: bvFTD),
expressive language (progressive non-fluent aphasia: PNFA,
logopenic progressive aphasia: LPA) or receptive language
(semantic dementia: SD) problems may experience compar-
able day-to-day functional burden but for different reasons. A
small study of 39 patients with non-specified dementia
showed that measures of everyday function were strongly
related to ACE-III performance, more so than to the MoCA
or the MMSE (Giebel & Challis, 2016). Because of the lim-
ited sample size and exploratory nature of the study, how-
ever, specific analyses in different subtypes of dementia were
not conducted.
This study aimed to establish the psychometric properties
of the ACE-III in a large population of healthy individuals
and patients with dementia to address some of the limitations
of previous studies. In doing so, this study aimed to: (i)
determine the nature and degree of any differences between
the ACE-III and ACE-R total and domain scores, as well as
provide a method to convert scores between the two tests; (ii)
establish appropriate dementia cutoff scores and “normal”
performance on the ACE-III, and (iii) examine the relation-
ship between ACE-III scores and everyday functioning,
stratified by dementia subtype.
This study was approved by the South Eastern Sydney
Local Area Health District and the University of New South
Wales Ethics committees. Consent to take part in the study
was obtained from all participants or their Person Respon-
sible in accordance with the Declaration of Helsinki.
STUDY 1: COMPARISONS BETWEEN THE
ACE-R AND ACE-III
Methods
Participants
Two hundred fifty-one individuals (199 diagnosed with
dementia; 52 healthy control volunteers) seen at FRONTIER,
the clinical dementia research group in Sydney, Australia,
were included in this study (Table 1). Patients were excluded
if they were not proficient in English, did not have a reliable
informant, or were unable to complete the assessment. All
patients underwent a clinical examination and cognitive
assessment and met the relevant clinical diagnostic criteria at
the time of testing: bvFTD (Rascovsky et al., 2011), typical
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Table 1. Study 1: Demographic characteristics for each patient group and heathy controls
Diagnosis
Control
(n= 52)
bvFTD
(n= 47)
AD
(n= 39)
SD
(n= 26)
NOS
(n= 20)
PNFA
(n= 17)
LPA
(n= 15)
CBS
(n= 15)
FTD-MND, MND or
mixed FTD
(n= 13)
PCA
(n= 4)
PSP
(n= 3)
Age 69.6 (6.7) 64.5 (9.8) 66.3 (9.0) 64.6 (7.1) 62.2 (10.5) 66.6 (8.6) 67.3 (6.1) 66.6 (6.2) 64.0 (8.4) 62.5 (5.1) 69.9 (5.1)
Education 13.9 (2.9) 12.5 (2.9) 12.6 (3.4) 12.8 (2.7) 10.8 (2.6) 14.0 (3.3) 11.2 (3.2) 11.0 (3.3) 12.4 (3.5) 12.0 (0.0) 8.7 (2.5)
Years since diagnosis — 5.4 (3.5) 4.5 (3.0) 5.6 (2.3) 4.7 (3.2) 3.7 (2.1) 3.9 (2.7) 3.7 (2.1) 2.3 (1.1) 3.3 (2.7) 5.4 (4.9)
ACE-III Total /100 95.7 (3.3) 73.6 (19.7) 65.3 (16.2) 55.4 (18.8) 75.4 (24.1) 78.1 (11.8) 52.1 (20.1) 79.0 (10.6) 72.5 (16.7) 40.8 (16.9) 71.7 (9.2)
ACE-III Attention /18 17.5 (0.9) 14.4 (4.0) 12.2 (3.7) 13.9 (3.5) 14.7 (4.9) 15.8 (2.3) 11.0 (4.4) 15.8 (2.0) 15.2 (2.7) 9.5 (2.4) 13.7 (2.1)
ACE-III Language /26 25.4 (0.8) 21.1 (5.1) 20.9 (4.9) 11.6 (5.7) 20.2 (6.9) 20.1 (3.6) 16.0 (6.6) 21.5 (3.1) 19.5 (3.3) 14.3 (7.6) 20.3 (6.4)
ACE-III Visuospatial /16 15.5 (0.9) 13.3 (3.5) 11.8 (3.7) 13.4 (2.5) 13.4 (3.5) 14.3 (2.2) 11.4 (3.6) 11.6 (3.4) 13.3 (2.3) 3.3 (1.7) 13.3 (2.3)
ACE-R Total /100 95.7 (2.6) 74.6 (19.5) 67.3 (16.5) 56.3 (18.5) 75.7 (24.5) 79.5 (11.5) 52.8 (20.2) 80.6 (9.7) 73.7 (15.7) 43.5 (17.1) 73.3 (11.6)
ACE-R Attention /18 17.9 (0.2) 15.3 (3.8) 13.7 (3.7) 14.9 (3.3) 15.3 (4.6) 17.0 (1.4) 11.8 (4.5) 16.6 (1.4) 15.8 (2.7) 10.8 (2.2) 16.3 (0.6)
ACE-R Language /26 25.3 (0.8) 21.1 (5.1) 21.3 (4.7) 11.4 (5.7) 19.8 (7.0) 20.1 (3.5) 15.9 (6.5) 22.2 (2.7) 20.1 (2.6) 15.8 (7.4) 19.3 (7.4)
ACE-R Visuospatial /16 15.5 (0.8) 13.5 (3.5) 11.8 (3.7) 13.5 (2.4) 13.5 (3.4) 14.4 (2.2) 11.5 (3.7) 11.7 (3.5) 13.3 (2.5) 3.3 (1.7) 13.3 (2.3)
CDR SoBa 0.5 (1.0) 5.5 (3.1) 4.2 (2.3) 5.0 (4.0) 4.6 (2.2) 2.0 (2.6) 3.4 (2.3) 2.8 (2.3) 5.6 (2.5) 5.0 (4.5) 5.0 (2.8)
CDR severity (0/0.5/1/2/3) 10/1/0/0/0 0/16/20/5/1 1/15/12/1/0 0/12/8/1/1 0/6/6/1/0 7/5/1/1/0 2/7/3/1/0 2/10/0/0/0 0/3/5/1/0 0/1/2/0/0 0/2/1/0/0
Note. Values are mean (standard deviation).
bvFTD= behavioral-variant frontotemporal dementia, AD=Alzheimer’s disease, SD= semantic dementia, NOS= dementia not otherwise specified, PNFA= progressive nonfluent aphasia, LPA= logopenic pro-
gressive aphasia, CBS= corticobasal syndrome, mixed FTD=mixed frontotemporal dementia, MND=motor neuron disease, FTD-MND= frontotemporal dementia-motor neuron disease, PCA = posterior cortical
atrophy, PSP= progressive supranuclear palsy; ACE-III=Addenbrooke’s Cognitive Examination – Third Edition, ACE-R=Addenbrooke’s Cognitive Examination – Revised, CDR=Clinical Dementia Rating Scale,
SoB=Sum of Boxes. a Number of missing values: Controls= 41, bvFTD= 5, AD= 10, SD= 4, NOS= 7, PNFA= 3, LPA= 2, CBS= 3, FTD-MND, MND or mixed FTD= 4, PCA= 1.
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AD (McKhann et al., 2011), PNFA, SD, LPA (Gorno-Tem-
pini et al., 2011), corticobasal syndrome (CBS) (Mathew,
Bak, & Hodges, 2012), progressive supranuclear palsy (PSP)
(Litvan et al., 1996), frontotemporal dementia-motor neuron
disease (FTD-MND) (Strong et al., 2009), motor neuron
disease (MND) (Costa, Swash, & de Carvalho, 2012), or
posterior cortical atrophy (PCA) (Tang-Wai et al., 2004).
Diagnosis was established by multidisciplinary consensus
between the neurologist, neuropsychologist and an occupa-
tional therapist after reviewing the clinical, cognitive, and
(when available) imaging data. Patients with reported cog-
nitive difficulties that did not fit within specific diagnostic
criteria for dementia, not otherwise specified (NOS), were
also included in the study.
Healthy controls were recruited from a research volunteer
panel and local community clubs. Similar to the patients, all
controls underwent cognitive testing and had a brain MRI
scan (see Supplementary Material for details of the cognitive
assessment of study participants). All healthy controls scored
88 or above on the ACE-R (Mioshi et al., 2006), with the
exception of one individual who scored 85, but was well-
within normal limits on all other neuropsychological tests
and displayed a normal MRI. Exclusion criteria for all parti-
cipants included prior history of mental illness, significant
head injury, movement disorders, cerebrovascular disease,
alcohol and other drug abuse, and limited English
proficiency.
Cognitive testing
All participants were tested on the same day on the ACE-R
and the addendum (novel) ACE-III items. To minimize
practice effects, the testing order was counterbalanced
whereby the ACE-III addendum items were administered
either before or after the administration of the ACE-R. The
ACE-III total score was calculated using the items common
to the ACE-III and ACE-R, together with the ACE-III
addendum items. Testing was conducted by a neu-
ropsychologist or researcher trained in cognitive assessment.
The addendum ACE-III items are described in detail in the
Supplementary Materials (see also Hsieh et al., 2013).
Statistical analyses
Data were analyzed using IBM SPSS version 24.0. Here,
analyses focused on the ACE-III scores that were modified
from their ACE-R counterparts (i.e., overall score and atten-
tion, language, and visuospatial scores). Scores were first
checked for normality using the Shapiro-Wilks Test. As the
results showed that none of these variables were normally
distributed (all p values< .001), the Wilcoxon Signed Rank
Test was used to compare ACE-III scores to their respective
ACE-R scores.
For Study 1, we used the data of all participants (n= 251)
and ran four linear regressions between the ACE-III (pre-
dictor variable) total, attention, language, and visuospatial
functioning scores and their respective ACE-R scores (out-
come variable). The regression equations obtained were used
to derive conversion formulae. This process was repeated
with each different dementia type, to obtain conversion for-
mulae between the ACE-III and ACE-R as a function of
diagnostic group.
Autocorrelation in these regression models was measured
using the Durbin-Watson test, and outliers were counted
(defined as cases with residuals> 2 standard deviations from
zero). Normality of residuals was assessed using the Shapiro-
Wilks test, while homoscedasticity was examined using a
scatterplot of residuals against the regression predicted
values.
Finally, we explored whether specific domain scores could
account for differences between the ACE-R and ACE-III.
First, the domain scores were converted into percentages.
Then, a two-way repeated-measures analysis of variance
(ANOVA) was conducted with test (ACE-R vs. ACE-III) and
cognitive domain (attention vs language vs visuospatial) as
the variables of interest. Helmert contrasts were conducted to
further characterize differences between the ACE-III and
ACE-R domain scores.
Results
Significant differences between the ACE-III and ACE-R
total, attention, and language scores were present (all p
values< .001). The visuospatial score was not significantly
different between test versions (Z= -.895; p= .371). Overall,
all regression equations were significant, indicating that per-
formance on these two versions of the ACE is highly related
(all p values< .001; Table 2). The regression equations were
used to convert between ACE-III and ACE-R total score and
domain scores. The analyses between these corresponding
scores demonstrated that overall, the ACE-III total and
Table 2. Study 1: Conversion equations between ACE-III and ACE-R scores and R2 values, all participants combined
Score Equation R2 Value
Overall ACE-III= -1.450 + 1.008(ACE-R) 0.993*
Attention ACE-III attention= -0.721 + 1.006(ACE-R attention) 0.930*
Language ACE-III language= 0.505 + 0.978(ACE-R language) 0.964*
Visuospatial ACE-III visuospatial= 0.097 + 0.995(ACE-R visuospatial) 0.997*
*= significant at the p< .001 level (outliers removed). A calculator to convert between ACE-R and ACE-III scores for each dementia type is provided in the
Supplementary Materials.
ACE-III=Addenbrooke’s Cognitive Examination – Third Edition, ACE-R=Addenbrooke’s Cognitive Examination – Revised.
Psychometric characteristics of the ACE-III 857
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1355617718000541
Downloaded from https://www.cambridge.org/core. University of Sydney Library, on 18 Oct 2018 at 23:51:13, subject to the Cambridge Core terms of use, available at
attention scores were consistently 1 point lower than their
ACE-R counterparts. Significant differences between pairs
were also present for the other cognitive domain scores but
reflected a difference of less than 1 point. Analyses conducted
on each dementia subtype separately provided similar results;
a 2- to 3-point drop was observed between ACE-R and ACE-
III total and attention scores, with the largest difference
observed in the CBS group.
Finally, a two-way repeated-measures ANOVA was car-
ried out on the scores to determine the source of differences
across ACE-R and ACE-III subtests. The analyses revealed a
significant test by domain interaction (F(2,500)= 64.655;
p< .001). Post hoc tests revealed that this interaction was
driven by the difference on the attention score between the
ACE-R and ACE-III (p< .001) and not the language and
visuospatial scores (p value= .541) (Figure 1).
Discussion
Our results revealed significant differences between the two
versions of the ACE for total and domain scores, with the
exception of the visuospatial domain score. Our regression
equations, however, demonstrated that the magnitude of
these differences is small, ranging between < 1 and 3 points
lower on the ACE-III than on the ACE-R, even when
accounting for different dementia types. Although statisti-
cally significant, these differences are unlikely to be clinically
meaningful. Our results also showed that differences between
the ACE-III and ACE-R were primarily driven by dis-
crepancies on the attention domain, with no appreciable dif-
ferences across the language and visuospatial domains
(Figure 1).
Having established the correspondence between the ACE-
R and the ACE-III, the next aim was to identify the most
relevant cutoff scores for dementia on the ACE-III in a large
undifferentiated sample of individuals with dementia.
STUDY 2: DEVELOPMENT OF ACE-III
CUTOFF SCORES FOR DEMENTIA
Methods
Participants
All 251 individuals from Study 1 (199 patients with demen-
tia; 52 healthy controls) were included in this study, as well as
an additional 167 participants (132 patients with dementia;
35 healthy controls) who had completed the ACE-III as part
of their clinical assessment, for a total of 418 individuals (331
dementia patients; 87 healthy controls) (Table 3; see Sup-
plementary Table 1 for the demographic characteristics of
each dementia group). Methods of recruitment and selection
of participants were identical to those described in Study 1.
Statistical analyses
For Study 2, before analyses, all variables were checked for
normality of distribution using Shapiro-Wilks test. Indepen-
dent t tests were run to examine potential differences in
demographic characteristics (e.g., age, education) between
the combined patient group and controls. Control perfor-
mance scores were used to generate a set of normative data
for the ACE-III total score and domain scores. Years of
education was missing for 8 healthy controls; their data were,
therefore, excluded from these analyses. Four two-way
ANOVAs were conducted to examine differences in ACE-
III total, attention, visuospatial, and language scores across
age (50–65 years vs. 66–71 years vs. 72 + years) and educa-
tion (< 14 years vs. ≥ 14 years) in the healthy controls.
A receiver operator characteristic (ROC) curve was used to
obtain sensitivity and specificity for a range of different cut-
off scores to differentiate between healthy controls and
patients with dementia using the entire sample. Positive and
negative predictive values for the same range of cutoff scores
were also calculated.
Results
Controls were significantly older than the patients with
dementia (mean difference= 2.8 years; t(419)= 2.734;
p= .007), and they had greater years of education (mean
difference= 1.7 years; t(408)= 4.615; p< .001) (Table 3).
Within the healthy control group, analyses showed no effect
of age on the ACE-III total or domain scores (all F tests<2;
Fig. 1. Differences between ACE-R and ACE-III domain scores.
The Attention and Orientation score has the greatest drop in score
from the ACE-R to the ACE-III.
Table 3. Study 2: Demographic characteristics for the healthy con-
trols and the dementia patient group
Controls (n= 87) Dementia patients (n= 331)
Age 67.3 (7.2) 64.5 (8.9)*
Education 13.9 (2.7) 12.2 (3.0)**
Disease duration — 4.6 (3.0)
*= significant at the p< .01 level, **= significant at the p< .001 level.
Values represent mean (standard deviation). In order of prevalence, the
dementia group include patients with behavioral-variant frontotemporal
dementia, Alzheimer’s disease, dementia not otherwise specified, semantic
dementia, logopenic progressive aphasia, progressive non-fluent aphasia,
corticobasal syndrome, mixed frontotemporal dementia or motor neuron
disease or frontotemporal dementia with motor-neuron disease, progressive
supranuclear palsy, and posterior cortical atrophy.
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p values> .24), and no interactions between age and educa-
tion (all F tests< 2; p values> .36). A significant main effect
of education was, however, observed on the ACE-III total
(F(1,73)= 9.930; p= .002), language (F(1,73)= 5.288;
p= .024) and memory scores (F(1,73)= 9.103; p= .004),
whereby higher education resulted in higher scores (Supple-
mentary Table 2). As such, we generated ACE-III normative
total and domain scores stratified into three age groups (50–
65 years, 66–71 years, 72 + years) and two levels of educa-
tion (≥ 14 years and<14 years) (Supplementary Table 3).
The ROC analysis revealed an area under the curve of .959
(95% CI .941–.976; p< .001), in differentiating patients
with dementia from healthy controls. Two optimal cutoff
scores were identified: A low cutoff score (84/100) which
maximized specificity (100%) with moderate sensitivity
(79%), and a high cutoff score (88/100), which improved
sensitivity (86%), while maintaining high specificity (95%).
Sensitivity and specificity, and positive and negative
predictive values, for scores between 80 and 90 are provided
in Table 4. Figure 2 shows the ACE-III scores of controls and
patients with dementia, with cutoff scores highlighted.
Discussion
Our analyses on ACE-III total scores identified two cutoff
scores that provide high sensitivity and specificity in detect-
ing dementia. The high cutoff score (88/100) is identical to
that of the ACE-R. Notably, however, the low cutoff score of
84/100 points, which achieves 100% specificity, while
retaining 79% sensitivity, is 2 points higher than its ACE-R
counterpart (Mioshi et al., 2006). This new cutoff likely
reflects the novel items used in the attention domain in the
ACE-III, as highlighted in Study 1.
STUDY 3: RELATIONSHIPS BETWEEN THE
ACE-III AND FUNCTIONAL IMPAIRMENT
Methods
Participants
One hundred ninety-four patients with dementia (bvFTD=
67; typical AD= 54; SD= 27; LPA= 23; PNFA= 23) from
Study 1 and 2 participated, each with an informant at the
assessment (Table 5). Patients with a predominantly motor
syndrome (i.e., CBD, PSP, FTD-MND) or with marked
vision impairment (i.e., PCA, PSP) were excluded. Methods
of recruitment, selection and assessment of study participants
were identical to those described in Study 1 and 2.
Cognition and dementia severity assessment
All patients completed the ACE-III. Spouses, relatives, or
carers of patients completed a questionnaire version of the
Clinical Dementia Rating Scale (CDR). The CDR is a clinical
staging tool that assesses six cognitive and functional
domains: memory, orientation, judgement and problem sol-
ving, community affairs, home and hobbies, and personal
care (Morris, 1997). The CDR Sum of Boxes (SoB) score
was used as an overall measure of functional ability, with
higher scores representing worse day-to-day functioning
Fig. 2. Distribution of ACE-III total scores in healthy controls and
patients with dementia. Lower and upper cutoff scores of 84 and
88 are displayed. Each dot represents one data point.
Table 4. Sensitivity, specificity, positive and negative predictive
values of the ACE-III according to total score
Score Sensitivity Specificity
Positive
Predictive Value
Negative
Predictive Value
80 0.70 1.00 1.00 0.46
81 0.72 1.00 1.00 0.48
82 0.74 1.00 1.00 0.50
83 0.76 1.00 1.00 0.52
84 0.79 1.00 1.00 0.56
85 0.82 0.99 1.00 0.59
86 0.83 0.98 0.99 0.59
87 0.84 0.97 0.99 0.62
88 0.86 0.95 0.99 0.63
89 0.87 0.94 0.98 0.65
90 0.90 0.92 0.98 0.71
Note. Recommended upper and lower bound cutoff scores are shaded in gray.
Table 5. Study 3: Demographic characteristics for the patient groups
bvFTD
(n= 67)
AD
(n= 54)
SD
(n= 27)
PNFA
(n= 23)
LPA
(n= 23)
Age 63.2 (9.3) 65.3 (9.1) 64.4 (6.9) 64.9 (10.2) 65.6 (6.8)
Education 12.3 (2.8) 11.8 (2.9) 12.6 (3.1) 12.6 (3.0) 11.7 (3.2)
Disease
duration
4.8 (2.9) 4.4 (3.2) 5.3 (2.2) 3.7 (2.1) 3.9 (2.7)
Note. Values are mean (standard deviation).
bvFTD= behavioral-variant frontotemporal dementia, AD=Alzheimer’s
disease, SD= semantic dementia, PNFA= progressive nonfluent aphasia,
LPA= logopenic progressive aphasia.
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(mild: 4.5–9.0; moderate: 9.5–15.5; severe:> 15.5) (O’Bry-
ant et al., 2008).
Statistical analyses
Patients were stratified by dementia subtype (AD, bvFTD,
PNFA, LPA, and SD), and general linear regression equa-
tions were obtained for each dementia subtype by regressing
the total ACE-III score (predictor variable) against the CDR
SoB (outcome variable). A regression model was also
obtained for the overall dementia group. Outliers in these
models, defined as cases with residuals> 2 standard devia-
tions from zero, were counted. Normality of residuals in these
regression equations was assessed using the Shapiro-Wilks
test and homoscedasticity was examined using a scatterplot
of residuals against the regression predicted values.
Results
No significant group differences were observed for age (F
(4,184)= 0.435; p= .783), education (F(4,184)= 1.179;
p= .322), or disease duration (F(4,184)= 1.564; p= .186)
across the different subtypes of dementia.
The regression equations between the ACE-III and the
CDR SoB were significant for all dementia subtypes with the
exception of the SD group. These models indicated that CDR
SoB accounted for between 17% (bvFTD) and 49% (LPA) of
the ACE-III score variance (Table 6). Some of the models
(bvFTD, PNFA, and Overall Dementia), however, were het-
eroscedastic and showed non-normally distributed residuals,
with several influential cases with high leverage.
Table 7 provides ACE-III total cutoff scores for different
functional severity levels in common dementia syndromes.
These scores were obtained by applying the dementia staging
SoB cutoff scores of the CDR (O’Bryant et al., 2008) to the
above mention regression equations (Table 6). These scores
varied for each group, but generally the cutoff for mild,
moderate, and severe dementia lay around 65, 50, and 20,
respectively. The bvFTD group consistently had the highest
score for each cutoff at 76, 62, and 43, while the LPA con-
sistently had the lowest score at each cutoff, at 54, 25, and 0.
Discussion
Consistent with previous work (Giebel & Challis, 2016), our
findings confirm the relationship between cognitive and
functional ability in dementia. Our analyses showed a sig-
nificant relationship between overall ACE-III performance
and CDR scores in all dementia subtypes, with the exception
of SD. Derived from our regression equations, we have pro-
vided ACE-III cutoff scores that correspond to the levels of
functional severity in the most common dementias (Table 7).
These cutoff scores should be interpreted with some caution
as some of the regression equations were found to violate
certain statistical assumptions. Nevertheless, these results
provide an important step toward understanding the rela-
tionship between cognitive deficit and functional impairment
in different dementia syndromes.
General Discussion
This study is the largest and most comprehensive investiga-
tion of the ACE-III to date. It demonstrates that, similar to its
predecessors, the ACE-III remains an excellent screening
tool for the identification of dementia (Hsieh et al., 2013;
Matias-Guiu, J.A., Cortes-Martinez, et al., 2017), even in a
large, heterogeneous dementia sample. We also reveal the
high sensitivity and specificity of the ACE-III, as well as its
relationship to functional impairment in the most common
dementia syndromes.
Since its significant revision in 2013, and the removal of
the MMSE items, one recurring question regarding the ACE-
III has been how well it compares to its predecessor, the
ACE-R. Here we demonstrate that, despite changes in several
items, the magnitude of difference between the ACE-R and
ACE-III total scores is negligible at a clinical level. In our
large sample of dementia patients, we found that the total
score on the ACE-III is broadly 1 point lower than on the
ACE-R, a difference that is primarily driven by changes in
the attention subscale (Ganguli et al., 1990). Accordingly,
patients initially assessed with the ACE-R can be confidently
reassessed with the ACE-III, given that the total and
remaining subdomain scores are comparable across versions.
Importantly, our analyses demonstrate that this con-
cordance between the two versions of the ACE holds irre-
spective of diagnostic category, albeit with some variation
contingent on dementia subtype. As such, in cases with an
established diagnosis, and where disease progression is of
primary interest, we provide a calculator to derive scores
between ACE versions for the main dementia syndromes
(Supplementary Materials; also available at www.ftdrg.org).
It is worth noting, however, that this calculator cannot
account for the variability in conversion scores as dementia
progresses. It may be the case that the neurodegenerative
process affects the corresponding items on the ACE-III and
ACE-R at different rates. Future studies may find it worth-
while to investigate the differences between the ACE-R and
ACE-III as a function of dementia severity. Additionally, this
calculator was developed using the English version of the
Table 6. Study 3: Regression equations as a function of diagnosis
Diagnosis Equation R2 Value
Overall ACE-III= 78.154 – 2.588 (CDRSoB) 0.150**
AD ACE-III= 81.559 – 4.005(CDRSoB) 0.264**
bvFTD ACE-III= 88.994 – 2.872 (CDRSoB) 0.174**
PNFA ACE-III= 79.508 – 2.821 (CDRSoB) 0.301*
LPA ACE-III= 80.309 – 5.824(CDRSoB) 0.494**
SD ACE-III= 63.036 – 1.338(CDRSoB) 0.089
*= significant at the p< .01 level, **= significant at the p< .001 level.
ACE-III=Addenbrooke’s Cognitive Examination – Third edition,
CDRSoB=Clinical Dementia Rating Scale Sum of Boxes score, AD=
Alzheimer’s disease, bvFTD= behavioral-variant frontotemporal dementia,
PNFA= progressive non-fluent aphasia, LPA= logopenic progressive
aphasia, SD= semantic dementia.
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ACE-R and ACE-III and, therefore, further studies of the
same nature will need to be conducted for non-English ver-
sions of the ACE.
The validity of the ACE-III as a screening instrument for
dementia with high diagnostic accuracy was further demon-
strated in Study 2 (see also Hsieh et al., 2013; Matias-Guiu,
Valles-Salgado, et al., 2017). Our analyses indicate that
whereas the original lower cutoff score of 82/100 retains
respectable sensitivity and specificity, a cutoff score of 84/
100 improves sensitivity without compromising the specifi-
city of the test. In contrast, the upper cutoff score of 88/100
remains unchanged.
The current study had some limitations. Our control group
was highly educated, with 70% of participants reporting
more than 12 years of education, compared to 28% reported
in the general Australian adult population over 65 years of
age (ABS, 2012), and demonstrated significantly higher
years of education than the dementia group. This is relevant
as positive correlations between ACE-III performance and
education have been reported (Jubb & Evans, 2015; Matías-
Guiu et al., 2016; Qassem et al., 2015). To this point, it is
possible that our highly educated control group inflated the
specificity and positive predictive values in Study 2 and,
therefore, false positives could occur when clinicians use our
revised recommended lower bound cutoff ACE-III score of
84/100 (compared with 82) in healthy individuals with less
than 12 years of education.
Furthermore, as the number of control participants was
quite low, the stratification process resulted in small numbers
of controls in each age and education cell. Additional inves-
tigations with larger samples of healthy individuals of a wider
range of educational backgrounds are, therefore, warranted. It
will be important to confirm these findings in cohorts of
individuals with diverse cognitive deficits, such as mild
cognitive impairment, and how performance in this popula-
tion compares to that of dementia patients. Similarly, it will
be important to establish the contribution of other potential
variables (e.g., age, socioeconomic status, cultural back-
ground) to test performance.
Finally, we identified a relationship between ACE-III and
functional ability as measured by the CDR, whereby cogni-
tive dysfunction was positively related to functional
impairment in all dementia groups, except SD. The most
robust statistical models were obtained for the AD and LPA
groups, a finding that may reflect the loading of memory and
orientation items on the CDR (Morris, 1997), and the fact that
these capacities are typically compromised in AD and LPA
(Flanagan, Tu, Ahmed, Hodges, & Hornberger, 2014;
Weintraub, Wicklund, & Salmon, 2012). In contrast, no sig-
nificant relationship between overall cognitive impairment
and functional decline was observed in SD. The CDR is
arguably less sensitive to focal language disturbances char-
acteristic of SD, prompting the development of the CDR-
FTLD, which incorporates language and behavior subscales
to improve its sensitivity to FTLD syndromes (Mioshi, Fla-
nagan, & Knopman, 2017).
We, therefore, recommend future FTD studies explore the
relationship between the ACE-III and CDR-FLTD and
recognize that this is a limitation of our study. Alternately,
given the relatively slow progression of SD, functional
decline may emerge at a much slower pace relative to other
neurodegenerative conditions (Mioshi, Hsieh, Savage,
Hornberger, & Hodges, 2010; O’Connor et al., 2016). For
example, SD patients may show marked cognitive impair-
ment yet continue to engage meaningfully in hobbies and
many activities of daily living (Graham, Lambon, & Hodges,
1997; Hodges et al., 2000). In this regard, we emphasize the
importance of taking into account the intricacies of each
dementia subtype when estimating the relative functional
impairment, and we caution that cognitive deficits do not
necessarily map consistently onto functional outcomes across
dementia syndromes. In that respect, future studies examin-
ing the type and sequence of functional changes (e.g.,
instrumental vs. basic functional abilities) and their relations
to cognitive deficits will be valuable in improving our
understanding of disease progression in dementia syndromes.
In summary, this body of work demonstrates that the ACE-
III is a valid and reliable cognitive screening test for the
detection of dementia, that it is an acceptable alternative to
the ACE-R, and that ACE-III performance relates to func-
tional ability in most common dementia syndromes.
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